Hidradenitis Suppurativa (HS)NCT07109765
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
An observational study of Hidradenitis Suppurativa (HS), run by Peking Union Medical College at 1 site in China.
Trial summary
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hidradenitis Suppurativa (HS)
- What is being tested?
- Secukinumab
- Type of treatment
- Injection or infusion
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2025to 1 Jun 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All participants were treated at the Department of Dermatology, Peking Union Medical College Hospital
Who may be able to join
- age ≥18 years
- diagnosis of moderate-to-severe HS with Hurley stage II or III
- Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
- inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors
Who cannot join
- active infections (e.g., viral hepatitis, active tuberculosis)
- use of other biologics or systemic immunosuppressants within the past three months
- severe organ dysfunction (e.g., hepatic or renal failure)
- any other conditions that might affect study results
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
No. 1 Shuai Fu Yuan, Dongcheng District, Beijing
Beijing, Beijing Municipality, 100730
Xiao Ma, 86-18511599355, maxiao9935@163.com
About this study
Official title: Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
- Conditions
- Hidradenitis Suppurativa (HS)
- Being tested
- Secukinumab
- Keywords
- Hidradenitis Suppurativa, Secukinumab, ultrasound
- Medical subject headings
- Hidradenitis Suppurativa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SecukinumabDrug
secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection
What is being measured
The primary outcome is the main question the study is designed to answer.
Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels
Measured: From enrollment to the end of treatment at Week 12
Secondary outcomes (1)
Dermatology Life Quality Index
Measured: From enrollment to the end of treatment at week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2025
- Study start1 Jun 2025
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hidradenitis Suppurativa (HS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiao Ma, Peking Union Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07109765
- Sponsor's protocol ID
- No. I-24PJ1844
- Status last verified
- Jul 2025
- First submitted
- 31 Jul 2025
- Last updated
- 7 Aug 2025
- Results posted
- No